C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
C07C 237/20 (2006.01) A61K 31/17 (2006.01) A61K 31/18 (2006.01) A61K 31/325 (2006.01) A61K 31/34 (2006.01) A61P 3/10 (2006.01) A61P 15/10 (2006.01) A61P 29/00 (2006.01) C07C 237/22 (2006.01) C07C 271/18 (2006.01) C07C 275/24 (2006.01) C07C 311/04 (2006.01) C07C 311/06 (2006.01) C07C 311/17 (2006.01) C07C 311/19 (2006.01) C07D 307/42 (2006.01)
Patent
CA 2379695
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, .beta..beta.-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
L'invention concerne certains composés, des procédés de préparation de ces derniers, des compositions pharmaceutiques les contenant, leur utilisation dans le traitement de maladies humaines ou animales. Les composés sont utiles comme modulateurs de l'interaction entre le récepteur destiné à des produits terminaux glyqués avancés (RAGE) et ses ligands, tels que des produits terminaux glyqués avancés (AGE), S100/calgranuline/EN-RAGE, beta -amyloïde et amphotérine, et pour la gestion, le traitement, la régulation ou comme traitement complémentaire de maladies humaines induites par RAGE. Ces maladies ou ces états maladifs regroupent des inflammations aiguës ou chroniques, le développement de complications tardives du diabète, telles qu'une perméabilité vasculaire accrue, la néphropathie, l'athérosclérose, et la rétinopathie, le développement de la maladie d'Alzheimer, les dysfonctionnements érectiles, l'invasion tumorale et les métastases.
Avor Kwasi
Gopalaswamy Ramesh
Mjalli Adnan
Patron Andrew
Wysong Christopher
Moffat & Co.
Transtech Pharma Inc.
LandOfFree
Compounds for modulating the rage receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for modulating the rage receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for modulating the rage receptor will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1622018